Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI

University Hospital, Caen1 site in 1 country178 target enrollmentNovember 2010

ConditionsAlzheimer's Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Alzheimer's Disease
Sponsor: University Hospital, Caen
Enrollment: 178
Locations: 1
Primary Endpoint: measuring the amplitude of the BOLD signal (Blood Oxygen Level Dependent)
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Investigators propose in this study to evaluate prospective memory (MP) in all its complexity as well as the processes, cognitive and brain, the underlying. Specifically, investigators propose to evaluate the evolution of the MP during normal aging and Alzheimer's disease (AD) to identify the cognitive and brain processes underlying this development. To do this, this study will have to include healthy subjects, 18 to 95 years, patients with Mild Cognitive Impairment (MCI) and patients with probable AD. All participants will undergo a series of examinations, both neuropsychological and brain imaging.

Registry

clinicaltrials.gov

Start Date

November 2010

End Date

December 2015

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University Hospital, Caen

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•All participants:
•Normal Education\> 7 years
•French mother tongue
•right-handed (Edinburgh Inventory)
•score on the scale of Beck \<7 (depression scale)
•signing the informed consent of the protocol in agreement with the Committee to Protect People
•Medical examinations, neurological, neuropsychological and neuroimaging depth in accordance with the specific inclusion and exclusion criteria for each population, that is to say:
•Young healthy subjects aged between 18 and 44 years
•Healthy subjects intermediate age: between 45 and 69 years
•score on the Mattis Dementia Scale higher than 137, in order to exclude any potential dementia

Exclusion Criteria

•Cognitive disorders of sudden onset (contrary to their slow and progressive onset in AD), which could reflect a stroke; a modified Hachinski ischemic score ≤ 2 (Loeb \& Gandolfo, 1983); history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;
•Chronic neurological disease, psychiatric, endocrine, hepatic, infectious;
•A history of major illness (chronic lung disease, heart disorder, metabolic, hematologic, endocrine or immunological severe, cancer);
•A medication that may interfere with the mnemonic or metabolic measures (psychotropics, hypnotics, anxiolytics, neuroleptics, anti-Parkinson, benzodiazepines, anti-inflammatory drugs, antiepileptics, antihistamines, analgesics and muscle relaxants central, as is usual The investigating doctor deems the annoying character for the study of the regular intake of certain medications). Taking anticholinesterase treatment will also be a criterion for non-inclusion.
•Chronic intake of alcohol or drugs;